Market Overview

Barrington Research: With SEC Litigation Settled, Opko Health Should Outperform

Share:
Barrington Research: With SEC Litigation Settled, Opko Health Should Outperform

Opko Health Inc. (NASDAQ: OPK) lost around 57 percent over the span of a few months after the SEC named the company as a defendant in a lawsuit alleging a "pump-and-dump" stock trading by CEO and Chairman Dr. Phil Frost.

The conclusion of the litigation — which ended with the company agreeing to pay a $100,000 penalty and Frost paying a $5-million fine — has been positive for the company’s shares, which have rallied more than 40 percent since December, according to Barrington Research.

The Analyst

Analyst Michael Petusky maintains an Outperform rating on Opko Health with a $7 price target. 

The Thesis

With the SEC issue behind it, Opko Health can now fully focus on growth, improving operations and making progress in its pre-commercial product pipeline, Petusky said in a Wednesday note. 

Opko Health has named Jon Cohen as executive chairman and Geoff Monk as president of its BioReference Laboratories business, which has been a major contributor to the company’s financial results.

While both moves appear positive, “we are particularly encouraged by Mr. Monk’s promotion given the fact that he has been charged with driving improvement in BRL’s operations since he was hired in May 2018,” the analyst said. 

Opko Health could generate revenue of $239.1 million in Q4, with BRL contributing approximately $190.3 million, according to Barrington. The company’s EPS for the quarter is projected at a negative 7 cents per share, Petusky said. 

Price Action

Opko Health shares were up 2.49 percent at $3.71 at the time of publication. 

Related Links:

Insider Buys Of The Week: FedEx, TechnipFMC, Opko Health

The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Latest Ratings for OPK

DateFirmActionFromTo
Nov 2019Piper JaffrayInitiates Coverage OnOverweight
Mar 2018JP MorganDowngradesNeutralUnderweight
Sep 2017JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for OPK
View the Latest Analyst Ratings

 

Related Articles (OPK)

View Comments and Join the Discussion!

Posted-In: Barrington Research Michael PetuskyAnalyst Color Price Target Reiteration SEC Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
KALUBenchmarkUpgrades
YEXTDA DavidsonMaintains20.5
BYDB of A SecuritiesMaintains47.0
SAICMorgan StanleyMaintains98.0
PVHMorgan StanleyMaintains104.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com